In a UK first, the Scottish authorities have changed their mind and agreed to fund Vertex’s cystic fibrosis drugs, Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor). The company and the government have struck an agreement under which Vertex will offer a confidential discount and a commitment to gather real world data on use of the products.
RWD Key To Scottish Orkambi Deal
Vertex has managed to secure a deal to provide Scottish cystic fibrosis patients with access to Orkambi and Symkevi. The promise of real world data and a price discount has convinced the Scottish government to say yes to the treatments, which had earlier been rejected by the Scottish Medicines Consortium.
More from Europe
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
The European Medicines Agency has recommended five drugs for EU-wide approval , including Averoa’s Xoanacyl for concomitant hyperphosphatemia. Two companies have withdrawn their marketing authorization applications.
More from Geography
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
• By
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.